Physician profile
Ross Zeltser
NPI 1194769851
$5,089.13
in general payments reported to CMS, 2019-2025
32 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $245 · 2021: $606 · 2022: $1,324 · 2023: $754 · 2024: $749 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $826.18 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $780.78 | 2019-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $449.54 | 2020-2025 | |
| Organogenesis INC. | $393.83 | 2021-2025 | Cygnus Dual, Puraply, Via Matrix |
| Lilly USA, LLC | $324.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $300.87 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $233.64 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $232.82 | 2021-2025 | |
| Incyte Corporation | $172.11 | 2022-2025 | Opzelura |
| Genentech USA, INC. | $159.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.17 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $129.98 | 2023-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $126.67 | 2024-2025 | Bimzelx |
| Convatec INC. | $96.10 | 2022 | |
| Leo Pharma INC. | $94.22 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $88.22 | 2022 | |
| Almirall LLC | $85.11 | 2019-2022 | |
| Biofrontera INC. | $70.45 | 2019-2022 | |
| Pfizer INC. | $64.21 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.34 | 2023-2025 | Cabtreo, Jublia |
| Journey Medical Corporation | $39.21 | 2022 | |
| Celgene Corporation | $36.17 | 2019 | |
| Vyne Pharmaceuticals INC. | $24.11 | 2021 | |
| Fresenius Kabi USA, LLC | $24.00 | 2023 | |
| Medtronic, INC. | $23.31 | 2024 | Closurefast |
| Verrica Pharmaceuticals INC. | $23.30 | 2023 | Ycanth |
| Mimedx Group, INC. | $21.72 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $21.05 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.62 | 2022 | |
| Mayne Pharma Commercial LLC | $18.40 | 2019 | |
| Dermavant Sciences, INC. | $17.16 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $14.77 | 2025 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Zeltser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.